Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bispecific antibody for multiple myeloma (MM) and application of bispecific antibody

A bispecific antibody, antibody technology, applied in the direction of antibody, application, fermentation, etc., can solve the problem of complex structure of bispecific antibody, and achieve the effect of ensuring biological activity, avoiding heterologous mismatch, and maintaining affinity

Active Publication Date: 2021-01-01
CHINA PHARM UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] But at the same time, bispecific antibodies are more complex in structure than monoclonal antibodies, and bispecific antibodies face greater challenges in the development of antibody drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific antibody for multiple myeloma (MM) and application of bispecific antibody
  • Bispecific antibody for multiple myeloma (MM) and application of bispecific antibody
  • Bispecific antibody for multiple myeloma (MM) and application of bispecific antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Construction of bispecific antibody DF00.

[0036] Firstly, the BCMA-targeting single-chain antibody 2A9 and the PD-1-targeting antibody D00, which were screened by the laboratory through phage display technology and optimized by the company, were used as templates to design primers to transfer the heavy and light chain variable region genes. The IgG4 constant region (the Fc segment is mutated by knobs-into-holes, and the Fab segment is transformed by Crossover) gene is used as a template to design primers to transfer the heavy and light chain constant region genes, and the variable and constant regions of the heavy and light chains are separated by overlapping PCR technology The heavy and light chain genes of the bispecific antibody DF00 were constructed by ligation; EcoRI and NotI double-enzyme digestion was performed on the obtained PCR product and pCMV3 vector respectively, and after recovering the target fragment and double-enzyme-digested vector, T4 DNA l...

Embodiment 2

[0037] Example 2 Expression, purification and identification of bispecific antibody DF00.

[0038] First, the four recombinant plasmids pCMV3-F00-H / L-Chain (knob end) and pCMV3-D00-H / L-Chain (hole end) were transfected into HEK293 cells by PEI transfection reagent in a certain ratio, and then Change the medium daily and passage the cells, gradually expand the scale of cell fermentation and culture, collect the cell culture medium, filter the sample with a 0.22 μm filter membrane, and then perform Protein A column affinity chromatography purification, and finally obtain a large amount of the target protein. 8% non-reducing and 12% reducing SDS-PAGE electrophoresis were performed respectively, and Western blotting was used to identify its molecular weight and assembly status, and to conduct preliminary verification of the target protein. see results figure 2 , F00 and DF00 were successfully expressed and assembled correctly.

Embodiment 3

[0039] Example 3 The binding affinity of DF00 to BCMA and PD-1 was verified by ELISA analysis.

[0040]First, the antigens BCMA and PD-1 were treated with 50mM NAHCO 3 The buffer was diluted to 1 μg / ml, and coated on the activated microplate at 4°C overnight; after washing with PBS to remove the antigen not bound to the plate, block with 5% skimmed milk at 37°C for 2 hours; wash the plate again with PBST Then start to incubate a series of diluted antibodies (500nM-0.244nM / 250nM-0.122nM) at 37°C for 2h; then wash the plate again with PBST to wash away the antibodies not bound to the antigen, and use goat antibody with HRP tag Incubate with human IgG (H+L) at 37°C for 2 hours; finally wash the plate with PBST and use TMB chromogenic solution to develop color. When a clear color gradient appears, use 2M dilute sulfuric acid to terminate the reaction and detect OD with a microplate reader 450 -OD 630 value as the final result. see results image 3 , the double antibody DF00 ha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a bispecific antibody for multiple myeloma (MM) and application of the bispecific antibody, and belongs to the technical field of genetic engineering antibodies. An antibody F00 targeting human BCMA and an antibody D00 targeting human PD-1 are used as parent antibodies, a 'knob' end and a 'hole' end are respectively introduced to two heavy chains Fc by a gene engineering technology according to a CrossMab platform, and a mammal eukaryotic expression system expresses DF00. The invention further provides a method for expressing and purifying the bispecific antibody DF00.A target protein is obtained through HEK293 cell secretory expression and affinity chromatography purification. The bispecific antibody DF00 can specifically bind to a BCMA molecule on the surface ofMM cells and an immune checkpoint molecule PD-1 on the surface of activated T cells at the same time, inhibit an immunosuppressive microenvironment in tumors and recruit T cells around the MM cells toremodel the MM cell killing function of the T cells.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering antibodies, in particular to a novel antibody that can simultaneously target human B-cell maturation antigen (B-cell maturation antigen, BCMA) and immunosuppressive molecule programmed death protein 1 (programmed cell death protein 1, PD -1) The bispecific antibody DF00, which can use dual targeting to recruit T cells expressing PD-1 antigen to the surrounding multiple myeloma cells with high expression of BCMA, and at the same time suppress the immunosuppressive microenvironment and reshape T cells. Cell killing effect on multiple myeloma cells. Background technique [0002] Tumor immunotherapy refers to the application of immunological principles and methods to specifically remove small residual tumor lesions, inhibit tumor growth, and break immune tolerance by activating immune cells in the body and enhancing the body's anti-tumor immune response. Tumor immunotherapy is to overcome...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C12N15/13A61K39/395A61P35/00A61P35/02
CPCC07K16/2878C07K16/2818A61P35/00A61P35/02C07K2317/31C07K2317/51C07K2317/515C07K2317/92C07K2317/73
Inventor 张娟李慧王阳王旻冯辉刘洪川
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com